Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 6Active not recruiting 2Terminated 1Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Myelodysplastic Syndromes 243Leukemia, Myeloid, Acute 191Leukemia 145Leukemia, Myelogenous, Chronic, BCR-ABL Positive 139Precursor Cell Lymphoblastic Leukemia-Lymphoma 120Myeloproliferative Disorders 89Multiple Myeloma 84Leukemia, Lymphocytic, Chronic, B-Cell 78Lymphoma, Non-Hodgkin 76Primary Myelofibrosis 72Leukemia, Myelomonocytic, Chronic 68Lymphoma 67Hodgkin Disease 66Leukemia, Myeloid, Chronic-Phase 55Lymphoma, Mantle-Cell 50Blast Crisis 49Lymphoma, Large B-Cell, Diffuse 47Lymphoma, Follicular 44Leukemia, Myeloid, Accelerated Phase 44Congenital Abnormalities 41Lymphoma, B-Cell, Marginal Zone 40Burkitt Lymphoma 40Neoplasms, Plasma Cell 38Lymphoma, Large-Cell, Immunoblastic 35Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 35Polycythemia Vera 32Hematologic Neoplasms 31Myelodysplastic-Myeloproliferative Diseases 30Lymphoma, T-Cell, Cutaneous 29Anemia, Refractory, with Excess of Blasts 29

Interventions

Imatinib Mesylate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Hypereosinophilic Syndrome × Myeloid × Clear all
NCT01066468 2012-03-13

Glivec/Gleevec Pediatric (Age 1 to Less Than 4) PK Study in CML, Ph+ ALL Patients and Other Glivec/Gleevec® Indicated Hematological Disorders.

Novartis

Phase 1 Terminated
3 enrolled
LymphoidMyeloidOther hematologic neoplasm

Pdgfra-Associated Chronic Eosinophilic Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Hypereosinophilic Syndrome, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡